Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Debt (2017 - 2023)

Historic Non-Current Debt for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2023 value amounting to $295000.0.

  • Autolus Therapeutics' Non-Current Debt rose 18095.24% to $295000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $295000.0, marking a year-over-year increase of 18095.24%. This contributed to the annual value of $116000.0 for FY2022, which is 937.5% down from last year.
  • As of Q3 2023, Autolus Therapeutics' Non-Current Debt stood at $295000.0, which was up 18095.24% from $122000.0 recorded in Q2 2023.
  • Over the past 5 years, Autolus Therapeutics' Non-Current Debt peaked at $295000.0 during Q3 2023, and registered a low of $30000.0 during Q3 2019.
  • Its 4-year average for Non-Current Debt is $127000.0, with a median of $118500.0 in 2019.
  • As far as peak fluctuations go, Autolus Therapeutics' Non-Current Debt plummeted by 9210.53% in 2019, and later surged by 18095.24% in 2023.
  • Quarter analysis of 4 years shows Autolus Therapeutics' Non-Current Debt stood at $30000.0 in 2019, then soared by 326.67% to $128000.0 in 2021, then dropped by 9.38% to $116000.0 in 2022, then surged by 154.31% to $295000.0 in 2023.
  • Its Non-Current Debt was $295000.0 in Q3 2023, compared to $122000.0 in Q2 2023 and $114000.0 in Q1 2023.